Connecticut Clinical Research Institute
Connecticut Clinical Research Institute
Bristol, Connecticut, United States5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| VE303 for Prevention of Recurrent Clostridioides Difficile Infection | Bacterial Infections and Mycoses, Clostridium difficile Infections, Clostridium difficile colitis, Clostridium infectious disease, Digestive System Diseases, Infections, bacterial infectious disease, central diabetes insipidus, digestive system disorder, dysentery, gastroenteritis, gram-positive bacterial infections, intestinal disorder | Recruiting | Phase 3 | 2026-09-29 | NCT06237452 | |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT04232553 | |
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have | Digestive System Diseases, Eosinophilia, Eosinophilic enteropathy, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, eosinophilic gastroenteritis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 2 | 2026-07-01 | NCT05831176 | |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | Barrett esophagus, Digestive System Diseases, digestive system disorder, esophageal adenocarcinoma, esophageal disorder, neoplasm, precancerous condition | Recruiting | Not applicable | 2026-07-01 | NCT05530343 | |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 2 | 2026-06-29 | NCT06851559 |